Investment Thesis
Verde Bio Holdings is in severe financial distress with collapsing revenues ($2.3K), massive operating losses (-$1.0M), and critically weak liquidity (0.06x current ratio). The company is burning cash (-$943.2K operating cash flow) with minimal equity cushion ($119.0K) and near-zero available capital, indicating imminent solvency risk.
APHD Strengths
- No long-term debt obligations reducing refinancing risk
- Positive stockholders equity remaining ($119.0K) though minimal
- Data available for analysis with 28 metrics reported
APHD Risks
- Revenue collapse of 100% YoY indicating business failure or operational shutdown
- Critically low current ratio of 0.06x with insufficient liquid assets to cover liabilities
- Negative cash flow generation (-$943.2K) unsustainable with only $11.6K cash on hand
- Extreme negative margins (operating margin -44,880%, net margin -92,359%) indicating operational non-viability
- Minimal equity base ($119.0K) provides negligible buffer for continued losses
- No insider activity in 90 days suggesting potential abandonment or distress
Key Metrics to Watch
- Quarterly revenue trends and operational status
- Cash position depletion rate and runway remaining
- Quarterly operating cash flow and path to profitability or restructuring
- Changes in liabilities and covenant violations
- Any material events, bankruptcy filings, or going concern disclosures
APHD Financial Metrics
APHD Profitability Ratios
APHD Balance Sheet & Liquidity
APHD 5-Year Financial Trend
5-Year Trend Summary: VERDE BIO HOLDINGS, INC.'s revenue has grown significantly by 8,529% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.53 indicates the company is currently unprofitable.
APHD Growth Metrics (YoY)
APHD Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2021 | N/A | -$4.3K | $0.00 |
| Q3 2019 | N/A | -$81.0K | $0.00 |
| Q2 2019 | N/A | -$122.4K | $0.00 |
| Q1 2019 | N/A | -$84.5K | $0.00 |
| Q3 2018 | $14.0K | -$12.9K | N/A |
| Q2 2018 | $16.8K | -$309.2K | N/A |
| Q1 2018 | $11.1K | -$84.5K | N/A |
| Q3 2017 | $22.5K | -$12.9K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
APHD Capital Allocation
APHD SEC Filings
Access official SEC EDGAR filings for VERDE BIO HOLDINGS, INC. (CIK: 0001490054)